Adds Global Patient Recruitment-retention Engine, Accelerating Clinical Trials
BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced that it has acquired a leading global patient recruitment and retention firm, MediciGroup®, Inc. (Medici). The acquisition includes affiliates MediciGlobal, Ltd. and Access to Patients, LLC. Medici also provides a lost-to-follow-up patient locate service (L2FU®) that finds missing patients globally. Together with Medici, BioClinica will offer pharmaceutical companies comprehensive patient recruitment and retention services that improve the speed and efficiency of global clinical trials.
"This exciting acquisition adds a powerful patient recruitment, retention and lost-to-follow-up engine to BioClinica," said BioClinica CEO John Hubbard, Ph.D. "Medici's proprietary technologies and processes ensure eligible patients are enrolled and retained in clinical trials, further accelerating clinical development timelines. As one company, we will bring a new clinical services model to our customers that is thoughtfully designed to achieve high-performance efficiencies in global trials."
Medici leads the industry in its ability to recruit patients from all over the world for clinical trials across numerous therapeutic areas, specializing in orphan disease and unique patient populations for hard-to-recruit clinical trials. Medici manages over 30 global patient communities online which, along with their patented tools and cutting-edge digital methodologies, help clients meet or exceed their recruitment goals. The company has implemented more than 200 programs for some of the world's largest pharmaceutical companies since its founding in 1992. Medici is distinguished by the quality of patients sent to sites based on a multi-step screening process using patented tools and digital methods. Its proprietary L2FU technology maintains clinical trial integrity and minimizes missing patient data by significantly reducing the number of patients lost to follow-up.
"We not only find your patients – we help keep them," said Liz Moench, founder and CEO, Medici. "Together with BioClinica, our services will deliver an important model focused on speed, quality and cost efficiency for clinical trials implementation. I find the openness of BioClinica's leadership to pursue new technologies and approaches especially exciting for our customers as we move toward the future."
BioClinica and Medici have already worked together on studies where the Medici Global team has leveraged data from BioClinica's technology. The two companies recently collaborated to complete enrollment for a global study ahead of schedule.
"When we integrate our recruitment metrics with BioClinica's system, we can manage clinical trials in real time. This enables us to monitor enrollment rates by sites and drive performance at all levels – recruitment marketing and site performance from start to end," said Moench.
About MediciGroup Inc.
MediciGlobal is in the business of making a meaningful difference to patient health—by identifying and engaging patients for clinical trials, and by building deep and lasting connections with its many stakeholders: patients, researchers and pharmaceutical sponsors. MediciGlobal's clinical trial recruitment practices are guided by global standards and by a concern for the lives of the patients who put their trust in the Medici team. MediciGlobal makes certain that those who participate in clinical trials fully understand what clinical trial participation means, and that their participation is guarded by strict privacy policies. MediciGlobal is an industry leader in the use of social media and internet-based technologies to connect patients with physicians to clinical trials and advance new medicines; its more than 30 Facebook communities exceed 1 million fans and more than 12 million visitors weekly. MediciGlobal meets BBB OnLine® and WBENC accreditation standards and is certified as a Safe Harbor company.